ALK is altered in 6.45% of mycosis fungoides patients [2].

ALK is an inclusion eligibility criterion in 1 clinical trial for mycosis fungoides, of which 1 is open and 0 are closed. Of the trial that contains ALK status and mycosis fungoides as inclusion criteria, 1 is phase 2 (1 open) [3].

BIRC2 is an inclusion eligibility criterion in 1 clinical trial for mycosis fungoides, of which 1 is open and 0 are closed. Of the trial that contains BIRC2 status and mycosis fungoides as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BIRC3 is an inclusion eligibility criterion in 1 clinical trial for mycosis fungoides, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and mycosis fungoides as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CARD11 is altered in 6.45% of mycosis fungoides patients [2].

CARD11 is an inclusion eligibility criterion in 1 clinical trial for mycosis fungoides, of which 1 is open and 0 are closed. Of the trial that contains CARD11 status and mycosis fungoides as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CD79A is an inclusion eligibility criterion in 1 clinical trial for mycosis fungoides, of which 1 is open and 0 are closed. Of the trial that contains CD79A status and mycosis fungoides as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CD79B is altered in 1.08% of mycosis fungoides patients [2].

CD79B is an inclusion eligibility criterion in 1 clinical trial for mycosis fungoides, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and mycosis fungoides as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NFKBIA is altered in 1.19% of mycosis fungoides patients [2].

NFKBIA is an inclusion eligibility criterion in 1 clinical trial for mycosis fungoides, of which 1 is open and 0 are closed. Of the trial that contains NFKBIA status and mycosis fungoides as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TNFAIP3 is altered in 6.45% of mycosis fungoides patients [2].

TNFAIP3 is an inclusion eligibility criterion in 1 clinical trial for mycosis fungoides, of which 1 is open and 0 are closed. Of the trial that contains TNFAIP3 status and mycosis fungoides as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].